ACP
XENE icon

Acuta Capital Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Acuta Capital Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-272,500
Closed -$9.84M – 48
2022
Q3 		$9.84M Hold
272,500
– – 4.24% 6
2022
Q2 		$8.29M Buy
272,500
+47,500
+21% +$1.44M 4.62% 6
2022
Q1 		$6.88M Hold
225,000
– – 3.21% 10
2021
Q4 		$7.03M Sell
225,000
-192,409
-46% -$5.75M 2.95% 11
2021
Q3 		$6.38M Hold
417,409
– – 2.25% 14
2021
Q2 		$7.77M Buy
417,409
+4,909
+1% +$90.5K 3.11% 9
2021
Q1 		$7.38M Buy
412,500
+332,500
+416% +$5.64M 2.66% 14
2020
Q4 		$1.23M Sell
80,000
-220,000
-73% -$2.57M 0.33% 41
2020
Q3 		$3.32M Sell
300,000
-217,500
-42% -$2.56M 0.9% 34
2020
Q2 		$6.49M Sell
517,500
-111,000
-18% -$1.41M 1.87% 23
2020
Q1 		$7.13M Sell
628,500
-289,000
-31% -$4.12M 3.45% 10
2019
Q4 		$12M Buy
917,500
+215,000
+31% +$2.26M 2.98% 11
2019
Q3 		$6.33M Buy
702,500
+1,000
+0.1% +$9.46K 4.57% 8
2019
Q2 		$6.92M Buy
701,500
+149,000
+27% +$1.43M 2.46% 16
2019
Q1 		$5.61M Buy
552,500
+15,000
+3% +$127K 2.67% 15
2018
Q4 		$3.39M Buy
537,500
+55,000
+11% +$489K 2.59% 14
2018
Q3 		$6.37M Buy
482,500
+32,500
+7% +$377K 2.27% 14
2018
Q2 		$4.14M Buy
+450,000
New +$2.8M 0.74% 27

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Acuta Capital Partners's XENE Position: Q4 2022 in Review

Acuta Capital Partners sold out of Xenon Pharmaceuticals (XENE) in Q4 2022, closing a stake of 272,500 shares — an estimated $9.84M sold.

Acuta Capital Partners first reported a position in XENE in Q2 2018 and held it in 18 quarters. The position peaked at $12M in Q4 2019. 159 funds tracked by Wall St. Rank hold XENE as of Q4 2022.

  • Acuta Capital Partners reported no remaining Xenon Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 272,500 Xenon Pharmaceuticals shares in Q4 2022, an estimated $9.84M.
  • Acuta Capital Partners first reported a position in Xenon Pharmaceuticals in Q2 2018 and held it in 18 quarters.
  • Acuta Capital Partners's Xenon Pharmaceuticals position peaked at $12M in Q4 2019.
  • 159 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.